Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 9/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433438 | 0.85 | CNR2 (0.45) | SLC6A4LMNAOPRM1OPRK1OGFRL1 | |
| SCHEMBL3433442 | 0.85 | CNR2 (0.45) | SLC6A4LMNAOPRM1OPRK1OGFRL1 | |
| SCHEMBL947139 | 0.81 | SLC6A4 (0.45) | SLC6A4OPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL945731 | 0.77 | CNR2 (0.40) | ALDH1A1 | |
| SCHEMBL3433332 | 0.77 | CNR2 (0.40) | ALDH1A1 | |
| SCHEMBL3434033 | 0.75 | HTR1A (0.37) | ALDH1A1 | |
| SCHEMBL1177022 | 0.74 | CYP2D6 (0.56) | HTR6LMNAOPRM1ALDH1A1 | |
| SCHEMBL28780669 | 0.72 | SLC6A4 (0.75) | GPR84SLC6A4HTR2ALMNAGLA | |
| SCHEMBL1176924 | 0.72 | HTR6 (0.64) | GPR84SLC6A4HTR2AHTR6AHR | |
| SCHEMBL1177387 | 0.72 | HTR6 (0.64) | GPR84SLC6A4HTR2AHTR6AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710054-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-04-29 | — | — | US | disclosed |
| EP-2170906-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-04-03 | — | — | EP | disclosed |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-28 | — | — | US | disclosed |
| US-8338592-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | GPR84 2634/4885SLC6A4 2949/4885HTR2A 2420/4885 |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | GPR84 2634/4885SLC6A4 2949/4885HTR2A 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.